ENZ: נכסי החברה Enzo

Enzo Biochem, Inc. (ENZ) is expanding B2B supplies of precision reagents and molecular systems to capture the diagnostics market. This price chart on GURU.Markets reflects that total assets amount to 233.66. Business resilience is supported by cash from the sale of the laboratory sector and the containment of operating expenses. Profitability is driven by the automated production of consumables for biomedical centers at minimal cost.

A reverse calculation of total resources via return on assets (ROA) allows for the cleansing of the fundamental balance sheet structure from temporary market distortions, revealing the real value of assets and liabilities. For Enzo Biochem, Inc. (ENZ), this trend reflects the efficiency of diversification between laboratory services and reagent production; therefore, analyzing the history of balance sheet assets helps investors identify capital overvaluation risks in a timely manner.